Arix Bioscience was a global venture capital firm focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. It was listed on the London Stock Exchange and sourced, financed, and built healthcare businesses at all stages of development.
74% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (48% of deals). Average disclosed round size is $71.9M (across 18 rounds with reported amounts).
Portfolio
18
Fund Size
$127M
Top Stage
Series B
Last 12 Mo
0
Team
CS
Christian Schetter
Managing Director
JT
Jonathan Tobin
Managing Director
TK
Tassos Konstantinou
Managing Director
TX
Tim Xu
Principal
FB
Felix Breyer
Analyst
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
23 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Ensoma | Series B | $135M | May 2023 |
 Evommune | Series B | $50M | Apr 2023 |
| SSorriso | Series A | $31M | Dec 2021 |
 Depixus | Series A | — | Dec 2021 |
 Disc Medicine | Series B | $90M | Sep 2021 |
| AArtios Pharma Limited | Series C | $153M | Jul 2021 |
 Amplyx Pharmaceuticals, Inc. | Series C | — | May 2020 |
 Quench Bio | Series A | $50M | Jan 2020 |
| SStipe Therapeutics | Series A | — | Oct 2019 |
 Artios | Series B | $84M | Aug 2018 |
| AArtios Pharma Limited | Series B | $84M | Aug 2018 |
| AArtios Pharma Limited | Series B | $84M | Aug 2018 |
| VVelosBio | Series B | $137M | Feb 2018 |
| AArtios Pharma Limited | Series B | — | Jan 2018 |
| AAtox Bio | Unknown | $30M | Dec 2017 |
 Autolus Therapeutics plc | Unknown | $80M | Sep 2017 |
| Amplyx Pharmaceuticals, Inc. | Series C | $67M | Aug 2017 |
 LogicBio | Series B | $45M | Jun 2017 |
| MMitoconix Bio | Series A | $20M | Jun 2017 |
 Harpoon Therapeutics | Series B | $45M | Jan 2017 |
| VVerona Pharma PLC | Unknown | $44.7M | Jun 2016 |
| Artios | Series C | — | — |
 Iterum Therapeutics | Series B | $65M | — |
Top Co-Investors
Sofinnova Partners10 shared
Andera Partners8 shared
Pfizer Ventures7 shared
SV Health Investors6 shared
M Ventures6 shared
RA Capital Management6 shared
OrbiMed6 shared
AbbVie5 shared
IP Group plc5 shared
Pappas Capital4 shared
New Enterprise Associates4 shared
EQT Life Sciences3 shared
Novartis Venture Fund3 shared
Pivotal Life Sciences3 shared
Cormorant Asset Management3 shared
Schroders Capital3 shared
Omega Funds3 shared
Avidity Partners3 shared
The Invus Group, LLC3 shared
Avid Ventures2 shared
Last updated: 7 October 2026